EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

David P Carbone iD, Tudor-Eliade Ciuleanu, Michael Schenker, Manuel Cobo, Stéphanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Niels Reinmuth, Eduardo Richardet, Ying Cheng, Hideaki Mizutani, Enriqueta Felip und 14 weitere

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2023-008189 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von David P Carbone und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and the Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or histology. We report updated efficacy and safety in all randomized patients with a minimum 4-year follow-up and an exploratory treatment-switching adjustment analysis in all treated patients who received chemotherapy and subsequent immunotherapy.

Methods

Adults with stage IV/recurrent non-small cell lung cancer (NSCLC), no sensitizing EGFR/ALK alterations, and ECOG performance status ≤1 were randomized 1:1 to nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with chemotherapy (two cycles) or chemotherapy (four cycles, with optional maintenance pemetrexed for the nonsquamous population). Assessments included OS, progression-free survival, and objective response rate. Exploratory analyses included efficacy by tumor PD-L1 expression and histology and in patients who discontinued nivolumab plus ipilimumab with chemotherapy due to treatment-related adverse events (TRAEs), and a treatment-switching adjustment analysis using inverse probability of censoring weighting.

Results

With a 47.9-month minimum follow-up for OS, nivolumab plus ipilimumab with chemotherapy continued to prolong OS over chemotherapy in all randomized patients (HR 0.74, 95% CI 0.63 to 0.87; 4-year OS rate: 21% versus 16%), regardless of tumor PD-L1 expression (HR (95% CI): PD-L1

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCarcinoma, Squamous CellAdultHumansNivolumabIpilimumabB7-H1 AntigenTreatment SwitchingNeoplasm Recurrence, Local

Stichwörter der Autor:innen

clinical trials, phase III as topicdrug therapy, combinationimmunotherapynon-small cell lung cancerprogrammed cell death 1 receptor

Substanzen

NivolumabIpilimumabB7-H1 Antigen

Autor:innen und Institutionen

  • Division of Medical Oncology and the Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA david.carbone@osumc.edu.
  • Department of Medical Oncology, Institutul Oncologic Prof Dr Ion Chiricută and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania.
  • Department of Medical Oncology, SF Nectarie Oncology Center, Craiova, Romania.
  • Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain.
  • L'institut du Thorax, Nantes, France.
  • Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain.

ORCID-Profile: David P Carbone

Förderung

  • Bristol Myers Squibb

Zitieren

APA

Carbone, D. P., Ciuleanu, T. E., Schenker, M., Cobo, M., Bordenave, S., Juan-Vidal, O., Menezes, J., Reinmuth, N., Richardet, E., Cheng, Y., Mizutani, H., Felip, E., Zurawski, B., Alexandru, A., Paz-Ares, L., Lu, S., John, T., Zhang, X., Mahmood, J., …, & Reck, M. (2024). Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008189

Vancouver

Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, et al. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008189

BibTeX
@article{Carbone2024,
  author = {Carbone, David P and Ciuleanu, Tudor-Eliade and Schenker, Michael and Cobo, Manuel and Bordenave, Stéphanie and Juan-Vidal, Oscar and Menezes, Juliana and Reinmuth, Niels and Richardet, Eduardo and Cheng, Ying and Mizutani, Hideaki and Felip, Enriqueta and Zurawski, Bogdan and Alexandru, Aurelia and Paz-Ares, Luis and Lu, Shun and John, Thomas and Zhang, Xiaoqing and Mahmood, Javed and Hu, Nan and De, Tuli and Santi, Irene and Penrod, John R and Yuan, Yong and Lee, Adam and Reck, Martin},
  title = {Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2023-008189}
}
Kostenlos starten →